A Double-blind Study of the Effectiveness of Cyclosporine in Amyotrophic Lateral Sclerosis

Stanley H. Appel, S. Scott Stewart, Vicki Appel, Yadollah Harati, William Mietlowski, William Weiss, George W. Belendiuk

Research output: Contribution to journalArticle

72 Scopus citations

Abstract

In a double-blind placebo-controlled trial of cyclosporine in amyotrophic lateral sclerosis, no differences were observed in the monthly rate of progression or the relative risk of progression in comparing 38 patients randomized to the placebo group and 36 patients randomized to the cyclosporine group. In comparing three subgroups of patients, cyclosporine appeared to benefit men who entered the study within 18 months of the onset of first symptoms, whereas it was of no value to women or to men who entered later than 18 months. For the men with recent onset of disease, the relative risk of progression was 0.403; the monthly rate of progression was 5.2 ± 1.1 points with placebo and 3.5 ± 0.7 points with cyclosporine. These provocative results support the need for a full study of cyclosporine in men with recent onset of disease.

Original languageEnglish (US)
Pages (from-to)381-386
Number of pages6
JournalArchives of neurology
Volume45
Issue number4
DOIs
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'A Double-blind Study of the Effectiveness of Cyclosporine in Amyotrophic Lateral Sclerosis'. Together they form a unique fingerprint.

Cite this